Duality Biotherapeutics Inc

DualityBio (9606.HK) Announces 2025 Annual Results

DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation

First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418